Ypsomed Holding AG's EBIT per Share for the
six
months ended in Mar. 2026 was CHF6.98.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was CHF17.92.
During the past 12 months, the average EBIT per Share Growth Rate of Ypsomed Holding AG was 118.70% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 58.80% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 78.40% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 11.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Ypsomed Holding AG's EBIT per Share or its related term are showing as below:
XSWX:YPSN'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -89.5 Med: 21.1 Max: 109.2
Current: 58.8
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Ypsomed Holding AG was 109.20% per year. The lowest was -89.50% per year. And the median was 21.10% per year.
XSWX:YPSN's 3-Year EBIT Growth Rate is ranked better than 92.03% of 690
companies
in the Medical Devices & Instruments industry
Industry Median: 9.5
vs XSWX:YPSN: 58.80
Ypsomed Holding AG (XSWX:YPSN) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Ypsomed Holding AG EBIT per Share Related Terms
Ypsomed Holding AG EBIT per Share Historical Data
* Premium members only.
The historical data trend for Ypsomed Holding AG's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF17.92
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ypsomed Holding AG (XSWX:YPSN) has a EBIT per Share of CHF17.92 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Ypsomed Holding AG and its competitors. According to the industry distribution chart, Ypsomed Holding AG ranks #55 out of 690 companies in the Medical Devices & Instruments industry, placing it in the top 8%.
Is Ypsomed Holding AG's EBIT per Share too high?
Ypsomed Holding AG's current EBIT per Share is CHF17.92. Based on the distribution chart, Ypsomed Holding AG ranks #55 out of 690 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Ypsomed Holding AG has a GF Score™ of 92/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ypsomed Holding AG's EBIT per Share compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Ypsomed Holding AG ranks #55 out of 690 companies for EBIT per Share. This places Ypsomed Holding AG in the top 8% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 9.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Devices & Instruments company?
The median EBIT per Share among Medical Devices & Instruments companies is 9.50, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Ypsomed Holding AG and its competitors. For the Medical Devices & Instruments industry, the median EBIT per Share is 9.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ypsomed Holding AG's current EBIT per Share is CHF17.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ypsomed Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Ypsomed Holding AG (XSWX:YPSN) is currently considered Fairly Valued. The stock's GF Value™ is CHF397.11, compared to a current price of CHF359.40 — trading 9.5% below its estimated fair value. The current EBIT per Share is CHF17.92. Ypsomed Holding AG's overall GF Score™ is 92/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Ypsomed Holding AG (XSWX:YPSN), the current EBIT per Share is CHF17.92 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ypsomed Holding AG (XSWX:YPSN) Overvalued in 2026?
Based on GuruFocus' analysis, Ypsomed Holding AG stock appears to be undervalued.
The current stock price of CHF359.40 is trading 9.5% below its estimated GF Value™ of CHF397.11.
GuruFocus considers Ypsomed Holding AG to be Fairly Valued.
Key valuation signals for XSWX:YPSN:
EBIT per Share: CHF17.92
GF Value™: CHF397.11 vs. price of CHF359.40 (9.5% below fair value)
No single metric tells the full story. See the XSWX:YPSN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ypsomed Holding AG is a Swiss company that develops and manufactures injection and infusion systems that allow patients to self-administer medication. Specifically, the company focuses on ensuring the ease of diabetes and insulin injection. The company offers various products such as pen needles with a click-on function. The company operates under two reportable segments: Ypsomed Delivery Systems and Ypsomed Diabetes Care.
92GF Score
Get the complete analysis for XSWX:YPSN
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:YPSN has been successfully added to your 
